On October 26, 2021, Quanta Therapeutics, Inc., a privately held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancer types, announced that it has successfully closed a $60 million Series C financing round led by Surveyor Capital (a Citadel company) and Vida Ventures. New investors Longitude Capital and BVF Partners joined existing investors Sofinnova Investments, Logos Capital, AbbVie Ventures, and Vida Ventures in the financing. Wilson Sonsini Goodrich & Rosati provided IP counsel to Quanta in connection with the Series C transaction.

Quanta will use the proceeds from the financing to advance programs targeting RAF1 and KRAS through clinical candidate selection and IND filing to reach initial proof-of-concept. Leveraging a differentiated mechanism targeting the active conformation of RAS, the Quanta team believes their unique approach, with applicability across mutant RAS forms, will circumvent resistance mechanisms experienced with first-generation inhibitors of KRAS G12C.

The Wilson Sonsini patents and innovations team that advised Quanta with respect to the financing was led by Julia Minitti and included Josh Seitz, Luis Perla, Jose Martinez, and Mike Hostetler.

For more information, please see Quanta’s press release.